<DOC>
	<DOCNO>NCT01924793</DOCNO>
	<brief_summary>This protocol seek enroll 60 immunocompromised subject diagnose parainfluenza infection . All subject additional PK Immunogenicity blood sample collect .</brief_summary>
	<brief_title>An Open Label Study Examine Effects DAS181 Administered Dry Powder Inhaler ( DPI ) Nebulized Formulation Immunocompromised Subjects With Parainfluenza ( PIV ) Infection</brief_title>
	<detailed_description>The study investigate safety , tolerability , clinical virologic effect DAS1814 treatment PIV infection 60 immunocompromised patient treatment option . Eligible immunocompromised patient positively diagnose PIV infection receive DAS181 DPI Nebulized formulation . DPI : 10 mg DAS181 administer seven ( 7 ) consecutive day total cumulative dose 70mg . Nebulized : DAS181 F02 formulation solution administer seven ( 7 ) consecutive day total cumulative dose 28.9 mg. Assessment viral shed viral resistance test perform collected viral load sample . Blood sample obtain evaluate safety schedule visit . Routine safety monitoring ( include Adverse Event ( AE ) reporting , clinical laboratory test , vital sign , electrocardiogram ( ECG ) ) 2 level ) conduct subject . A final safety assessment occur Day 28 ( +/- 2 day ) enrollment/first dose study drug . Survival , diary card , quality life collect Day 60 90 . PK collect visit subject baseline/visit 2 visit 11/Day 28 . Immunogenicity sample collect select time point subject .</detailed_description>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<criteria>1 . Age â‰¥12 year 2 . Able provide inform consent child assent parental consent 3 . Immunocompromised , define one following : Allogeneic hematopoietic cell transplantation ( HCT ) Lung lungheart transplantation Patients treat chemotherapy hematologic malignancy autologous HCT 4 . Confirmed Parainfluenza virus nasopharyngeal swab tracheal aspirate one following : Respiratory virus panel DFA Qualitative/quantitative RTPCR test parainfluenza virus perform local laboratory ( confirmatory PCR test do central lab require start patient study ) . 5 . Female subject childbearing potential capable conception must : postmenopausal ( one year great without menses ) , surgically incapable childbearing , practice two effective method birth control . Acceptable method include intrauterine device , spermicide , barrier , male partner surgical sterilization hormonal contraception . A female subject must agree practice two acceptable method birth control 28 day study period . Abstinence acceptable method contraception . All reproductive female subject must negative serum pregnancy test screen visit . 6 . Male subject must agree use medically accept form contraception 28 day study period . 1 . Psychiatric cognitive illness recreational drug/alcohol use , opinion principal investigator , would affect patient safety and/or compliance . 2 . Any significant finding patient 's medical history physical examination , opinion investigator , would affect patient safety , ability use dry powder inhaler compliance dose schedule . 3 . Subjects currently treat oral , aerosolized IV ribavirin 4 . Subjects take investigational drug use research treat PIV</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>